CapRegen First Day of Dealing

RNS Number:7387A
Tarsus Group PLC
24 July 2007


24 July 2007

                                Tarsus Group PLC

                        CapRegen plc - Admission to AIM



Tarsus Group plc (LSE: TRS) ('Tarsus'), the international media group with
interests in exhibitions, conferences, publishing and online media, is delighted
to announce that CapRegen plc ('CapRegen') has been admitted to AIM after
successfully raising #3.2 million, before expenses, by way of a placing with
institutional and other investors at a placing price of 5p per Ordinary Share of
1p each (the 'Placing Price'), valuing the CapRegen's issued ordinary share
capital at #4,450,500 on Admission.


Following the placing, Tarsus has a beneficial ownership of 15,500,000 Ordinary
Shares in CapRegen (worth #775,000 at the Placing Price), representing 17.4% of
CapRegen's enlarged issued share capital.


CapRegen is a newly incorporated public limited company that has been
established in order to make investments in the global anti-ageing and
regenerative medicine market place. CapRegen will use the expertise of Dr Robert
Goldman, PhD, DO, FAASP and Dr Ronald Klatz., D.O. to invest in medical
technologies that they and the other Directors believe have commercial
viability.


Dealings in CapRegen's shares commenced as of 8.00am today, 24 July 2007 under
the ticker symbol CGN. Further information about CapRegen's is available in its
announcement released today.



Douglas Emslie, Group Managing Director of Tarsus Group plc and Chairman,
CapRegen plc said:


"CapRegen's IPO is an exciting development for Tarsus and follows the
acquisition of MCII which owns and operates the three leading medical sector
exhibitions and conferences in the US anti-ageing market. MCII's first major
medical event of the year in Orlando was significantly ahead of the prior year
with revenues up 112%.


"Tarsus now has extensive knowledge of the anti-ageing market and CapRegen
brings together specific healthcare and investment expertise to capitalise on
opportunities in this fast growing sector. With a number of potential investee
companies already available to the company, CapRegen is in an extremely strong
position to generate exciting returns for its shareholders."


Enquiries:
Tarsus Group plc                                          020 8846 2700
Doug Emslie, Group Managing Director

Madano Partnership                                        020 7593 4000
Mark Way / Matthew Moth

IR Focus                                                  020 7593 4000
Neville Harris




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCVZLBLDDBFBBX

Capregen (LSE:CGN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024